ABSTRACT. Patients with cystic fibrosis and pancreatic sufficiency were investigated for evidence of progressive pancreatic disease. From a cohort of 630 patients, 20 pancreatic-sufficient patients became pancreatic insufficient after an average duration of 5.6 y (range 0.6-20.6 y) from diagnosis. Among 54 patients documented to be pancreatic sufficient by direct pancreatic stimulation test, 47 remained pancreatic sufficient and seven developed pancreatic insufficiency. The patients who ultimately developed pancreatic insufficiency were younger and had greatly reduced outputs of enzyme, fluid, and electrolytes. Those who remained pancreatic sufficient showed enzyme secretion close to or within the non-cystic fibrosis control range. Twenty of these patients underwent a second pancreatic stimulation test after an average interval of 4 y (range 1.3-6.2 y). No significant alteration in enzyme, fluid, or electrolyte output was seen in the patients who remained pancreatic sufficient, but there was further reduction in enzyme and fluid output in the patients who developed pancreatic failure. In conclusion, the majority of pancreatic-sufficient patients with pancreatic enzyme secretion within the control range showed no deterioration of function over an extended time period. However, a small number of pancreatic-sufficient patients with reduced enzyme and fluid secretion are at risk of pancreatic failure. (Pediatr Res 32: 179-182, 1992) in CF neonates diagnosed by newborn screening reveal that 38% of CF infants are pancreatic sufficient at diagnosis (3), but 21% of these patients develop pan creatic insufficiency between 3 and 36 mo of age. This observation supports the previous suggestion that some pancreatic-sufficient patients will develop pancreatic insufficiency with advancing age. Also, in nonscreened populations , the variable age of diagnosis and modes of clinical presentation may be attributed to varying onset of signs and symptoms of pancreatic failure.
ABSTRACT. Patients with cystic fibrosis and pancreatic sufficiency were investigated for evidence of progressive pancreatic disease. From a cohort of 630 patients, 20 pancreatic-sufficient patients became pancreatic insufficient after an average duration of 5.6 y (range 0.6-20.6 y) from diagnosis. Among 54 patients documented to be pancreatic sufficient by direct pancreatic stimulation test, 47 remained pancreatic sufficient and seven developed pancreatic insufficiency. The patients who ultimately developed pancreatic insufficiency were younger and had greatly reduced outputs of enzyme, fluid, and electrolytes. Those who remained pancreatic sufficient showed enzyme secretion close to or within the non-cystic fibrosis control range. Twenty of these patients underwent a second pancreatic stimulation test after an average interval of 4 y (range 1.3-6.2 y). No significant alteration in enzyme, fluid, or electrolyte output was seen in the patients who remained pancreatic sufficient, but there was further reduction in enzyme and fluid output in the patients who developed pancreatic failure. In conclusion, the majority of pancreatic-sufficient patients with pancreatic enzyme secretion within the control range showed no deterioration of function over an extended time period. However, a small number of pancreatic-sufficient patients with reduced enzyme and fluid secretion are at risk of pancreatic failure. (Pediatr Res 32: [179] [180] [181] [182] 1992) in CF neonates diagnosed by newborn screening reveal that 38% of CF infants are pancreatic sufficient at diagnosis (3), but 21% of these patients develop pan creatic insufficiency between 3 and 36 mo of age. This observation supports the previous suggestion that some pancreatic-sufficient patients will develop pancreatic insufficiency with advancing age. Also, in nonscreened populations , the variable age of diagnosis and modes of clinical presentation may be attributed to varying onset of signs and symptoms of pancreatic failure.
There are few data concerning longitudinal changes of exocrine pancreatic function in patients with pancreatic sufficiency. Our current cross-sectional data suggest that pancreatic-sufficient patients are capable of secreting adequate amounts of pancreatic enzymes to ensure normal digestion, but it is important to emphasize that this subgroup of CF patients is characterized by a wide range of acina r capability, from mean values similar to control subjects to enzyme secretory rates as low as I to 2% of the mean normal rate (4). The wide variation of exocrine pancreatic function in pan creatic-sufficient patients together with the fact that these parti cular patients are prone to recurring attacks of acute pancreatitis (5) strongly suggest that ongoing pancreatic damage occurs . To evaluate this possibility, we have assessed pancreatic-sufficient patients for evidence of progressive pancreatic disease and have attempted to characterize those at risk of developing pancreatic failure. Patients. All patients attending the CF Clinic at The Hosp ital for Sick Children, Toronto undergo comprehensive clinical evaluation at diagnosis. After confirmation of the diagnosis by at least two elevated sweat chloride determinations (> 60 mmol/ L), the patient's pulmonary, nutritional , and pancreatic status is determined. This stud y includes a cohort of 630 patients who were assessed for pancreatic status by a combination of techniques , which are outlined below. Those with documented pancreatic insufficiency are prescribed pancreatic enzym e supplements with meals. Patients with pancreatic sufficiency, who do not require enzyme supplementation, are carefully monitored for evidence of pancreatic failure. Fifty-four pancreatic-sufficient patients (mean age 13.0 ± 9.9 y; range 0.2-37.9 y; 34 males) were quantitatively evaluated by direct pancreatic function test, and exocrine pan creati c function was evaluated longitudinally using a combination of assessment techniques (described below) to monitor their pancreatic function status . Twenty of these patients (mean age 10. (1) recognized that a small subset of patients with CF had sufficient pancreatic function to maintain normal digestion without the need for exogenous pancreatic enz yme supplements. We have coined the term "pancreatic sufficient " to describe CF patients with normal digestion, which serves to distinguish them from those with pancreatic insufficiency who have fat maldigestion due to pancreatic failure. The exact proportion of pancreatic-sufficient and pancreatic-insufficient patients in the CF population has not been precisely defined . Our cross-sectional clinical data suggest that 12 to IS% of the population are pancreatic sufficient (2) . However , recent data 180 COUPER ET AL. Test 2 shows the fecal fat data when pancreatic insufficiency occurred. Two patients were less than 6 mo of age when first tested (noted by asterisk).
Direct evaluation ofpancreaticfunction in pancreatic-sufficient subjects. Among the 54 CF subjects documented to be pancreatic-sufficient by direct pancreatic stimulation test, 47 remained pancreatic sufficient. The remaining seven patients developed pancreatic insufficiency. At the initial evaluation, the mean age of the patients who developed pancreatic failure was 3.3 ± 3.6 y (range 0.5-9.9 y), which was significantly younger than the 47 patients who remained pancreatic sufficient (mean age 14.4 ± 9.8 y; range 0.2-37.9 y; p < 0.0001). Pancreatic insufficiency occurred shortly after an elapsed time of 4.0 ± 2.8 y (range 1.1-7.4 y). In contrast, the CF patients who remained pancreatic sufficient retained their pancreatic-sufficient status for a mean duration of6.4 ± 3.0 y (range 0.3-12.7 y) from diagnosis. Examination of the initial pancreatic stimulation test results (Table 1) shows a wide range of values for all parameters of pancreatic function. The patients who remained pancreatic sufficient had significantly greater pancreatic fluid output and enzyme secretion than those who developed pancreatic insufficiency.
Twenty pancreatic-sufficient patients underwent a second pancreatic stimulation test after an average interval of 4.0 ± 1.4 y (range 1.3-6.2 y). The outputs of enzyme, fluid, and electrolytes for the first and second stimulation tests are shown in Table 2 . Sixteen patients remained pancreatic sufficient over a mean period of 4.4 ± 2.6 y. No significant alteration in enzyme, fluid, or bicarbonate secretion was seen in the patients who remained pancreatic sufficient. Four patients developed pancreatic insufficiency, but in three pancreatic failure occurred shortly after the second test was performed. In those who became pancreatic insufficient, the initial stimulation test showed markedly reduced enzyme and electrolyte output, and, when retested after an average elapsed time of 3.0 ± 2.2 y (range 1.3-5.5 y), there was further reduction in trypsin, lipase, and colipase output. The alteration in fluid output was less pronounced, and bicarbonate secretion, which was already low, showed no change.
I-<C
l..l.. have been established as a clinical routine for patients attending the CF Clinic. However, some of the pancreatic stimulation tests were performed as part of research studies, which were approved by the institutional review board and with informed consent from each patient and/or guardian.
Pancreatic function was assessed by one or more of three methods. Three-to 5-d pooled stool collections were obtained and stored at 40C and fecal fat content was determined by the method of van de Kamer et al. (6) . In patients receiving mediumchain triglycerides, the fecal fat content was analyzed by the method of Jeejeebhoy et al. (7) . If the patient had been receiving pancreatic enzymes with meals, enzyme supplements were discontinued at least 48 h before commencement of the stool collection. Fecal fat excretion, expressed as a percentage of mean daily fat intake, was calculated by weighing food intake and by reference to standard food content tables. Pancreatic sufficiency was defined as a fecal fat excretion of ::5.7% in patients older than 6 mo of age or ::5.15 % in patients under 6 mo of age (8) .
Serum cationic trypsinogen was measured by a double antibody RIA procedure as described previously (9, 10) . Crosssectional analysis of our CF population has shown that levels below the reference range (16.9-46.5 J.Lg/L) are a reliable predictor of pancreatic insufficiency, and this is a consistent observation in pancreatic-insufficient patients with CF who are older than 7 y of age (11) . This evaluation was performed every 6 to 12 mo. In the majority of subjects, if this test suggested that a patient had developed pancreatic insufficiency or if clinical symptoms suggested pancreatic failure, a fat balance study and/or pancreatic stimulation test was performed as well.
The direct pancreatic stimulation test was performed according to a previously described and validated duodenal marker perfusion technique while maximally stimulating pancreatic secretions with i.v. secretin and cholecystokinin (12, 13) . Duodenal aspirates were analyzed for colipase, total lipase, and tryptic activity by titermetric techniques (4, 14) . Bicarbonate was measured by a colorimetric technique (15) , and sodium, potassium, and chloride concentration by flame emission photometry. Patients were considered to be pancreatic sufficient if colipase output exceeded 120 U/kg body wt/h or trypsin output exceeded 50 U/kg body wt/h (4, 13).
Data analysis.
All results are expressed as the mean ± 1 SD.
Comparisons were made using the unpaired t test assuming equal or unequal variance of data as appropriate. p values below 0.05 were regarded as significant. All data were analyzed using the Statistical Analysis System.
RESULTS
Progression from pancreatic sufficiency to pancreatic insufficiency. Out of 630 patients assessed for pancreatic status, 20 were pancreatic sufficient at diagnosis but later became pancreatic insufficient. The mean age at diagnosis was 3.5 ± 4.7 y (range 0.2-14.1 y). Pancreatic insufficiency became manifest after an average duration of 5.6 ± 3.9 y (mean age of 9.1 ± 5.9 y; range 0.6-20.6 y). Six patients developed pancreatic insufficiency before 5 y of age, eight were between 5 and 10 y, and six were older than 10 y. In 14 of these patients, progression to pancreatic failure was documented by serial fecal fat determinations (Fig.  1) . Two patients who had normal fecal fat determinations when first tested subsequently developed low serum cationic trypsinogen determinations (14.8 and 7.9 J.Lg/L) at 15.2 and 16 y of age, respectively. In another patient, fecal fat determination confirmed the pancreatic-sufficient status at diagnosis, and a pancreatic stimulation test performed 1.3 y later confirmed progression to pancreatic insufficiency. In the remaining three patients, the presence of pancreatic sufficiency was documented at diagnosis (0.6-0.75 y) by direct pancreatic function test; two showed reduced serum cationic trypsinogen levels (1.0 and 12.9 J.Lg/L at 8.25 and 7.0 y, respectively), and the third exhibited pancreatic failure on the basis of a second pancreatic stimulation test. 
DISCUSSION
This study documents for the first time that the majority of CF patients who are pancreatic sufficient at diagnosis maintain sufficient exocrine pancreatic function to facilitate normal nutrient assimilation for long periods of time. These data were obtained by using a combination of previously validated tests to identify pancreatic-sufficient patients and to monitor disease progression. A subset of pancreatic-sufficient patients developed pancreatic insufficiency over a variable period of time. Differences in pancreatic function were identified when the two groups were compared. Pancreatic-sufficient patients who ultimately developed pancreatic insufficiency had greatly reduced fluid, electrolyte, and enzyme secretions when first tested in comparison with those who remained pancreatic sufficient. As expected, serial assessment revealed a further reduction in fluid and enzyme secretion.
Pancreatic disease in CF is due to a primary defect in epithelial electrolyte permeability within the ducts that results in reduced ductular fluid flow, producing hyperconcentrated proteinaceous secretions that precipitate and block pancreatic ductules (16, 17) . This observation is based on direct evidence of reduced fluid output and increased concentration of secreted proteins in comparison with matched non-CF subjects (18) (19) (20) (21) (22) . The finding of a greater reduction of fluid output in tandem with reduced enzymatic output in pancreatic-sufficient patients who develop pancreatic failure provides strong evidence for progressive pathology presumably due to ductal obstruction and acinar atrophy. However, the number of pancreatic-sufficient patients who progress to pancreatic insufficiency represents a small minority of a crosssectional CF population. These data contrast with the recent report of Waters et al. (3) , who revealed that 38% ofCF patients diagnosed by newborn screening were pancreatic sufficient; approximately 20% of the patients developed pancreatic failure by 3 y of age. The high proportion of pancreatic-sufficient patients in Waters' study and the large percentage who developed pancreatic failure can be attributed to early diagnosis. In the absence of a newborn screening program, many of these patients would not have been diagnosed until symptoms of maldigestion became manifest. Indeed, most of our pancreatic-sufficient patients who became pancreatic insufficient did so before 10 y of age.
The presence or absence of exocrine pancreatic insufficiency is of prognostic importance. Those with pancreatic sufficiency are diagnosed at a later age, presumably because of milder symptoms, have lower mean sweat chloride levels, maintain better pulmonary function with age, and are less likely to have pulmonary colonization with Pseudomonas infections (2, 23).
They grow normally in childhood and generally do not lose weight as adults. Survival is far superior to those with pancreatic insufficiency. We have shown that genetic factors influence the degree of pancreatic disease and probably its rate of progression. In support of this, we have observed remarkable concordance of pancreatic function status among affected members within the same family (24) . We also noted a striking difference between pancreatic-sufficient and pancreatic-insufficient groups with respect to allelic and haplotype distribution of DNA markers tightly linked to the CF locus (25) . This finding has now been confirmed after identification and isolation of the CF gene and delineation of the major CF mutation (Li.Fsos), a 3-bp deletion resulting in the loss of single phenylalanine residue at amino acid position 508 of the predicted gene product (26) (27) (28) (29) . These data suggest that the variable clinical expression of disease is in part attributable to specific mutations at the CF locus.
Identification of the various mutations in the CF gene is also important because their characterization may provide insight into the molecular consequences of CF. For example, it is quite likely that mutant alleles giving rise to mild disease expression may occur as a result of derangement of the putative CF protein, which may not impair transmembrane ion transport as severely. The identification of various mutant alleles may lead to the identification of a variety of functional defects and eventually may provide alternative pharmacologic mechanisms whereby the underlying functional defect can be promoted, bypassed, or replaced. Further characterization of the differences in phenotypic expression of pancreatic disease in CF at the cellular and molecular level will help to facilitate such advances.
